Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia.
ABSTRACT It has been recently established that serum from human volunteers immunized with E. coli J5 vaccine prevents death of patients with gram-negative shock. The present study addressed the question whether the prophylactic administration of a similar amount of J5 antiserum could protect neutropenic patients from acquiring gram-negative infections. One hundred patients, the majority of which had acute non-lymphoblastic (63%) and lymphoblastic (29%) leukemia, presented 109 episodes of neutropenia. Sixty of the 100 patients underwent bone marrow transplantation. All patients were given one unit of either pre-immune (control) or J5 antiserum serum from volunteers at the onset of neutropenia. When compared to control serum, J5 antiserum given prophylactically did not reduce the number of febrile days, the number of gram-negative bacteremic episodes, or death from these infections. This inability to demonstrate a beneficial effect of prophylaxis with a single unit of J5 antiserum in prolonged neutropenia may have several explanations that are discussed.
- [Show abstract] [Hide abstract]
ABSTRACT: In a case-control study, evidence of previous epilepsy was sought in 230 consecutive patients under the age of 70 admitted to hospital with acute stroke. 8 (4.5%) of the 176 patients having their first stroke were epileptic, compared with 1 (0.6%) of the matched controls. 6 of the 8 epileptics started their seizures after the age of 30 years. 5 (9.3%) of the 54 patients who had had a previous stroke were epileptic, compared with none of the control patients. The findings support the idea that otherwise clinically undetectable cerebrovascular disease may present with seizures and that these can be a warning sign for a future stroke.The Lancet 02/1987; 1(8523):11-3. DOI:10.1016/S0140-6736(87)90701-X · 39.21 Impact Factor
- Veterinary Immunology and Immunopathology 11/1985; 10(1):71-127. DOI:10.1016/0165-2427(85)90039-X · 1.75 Impact Factor
- Journal of Pediatrics 11/1993; 123(4):497-508. DOI:10.1016/S0022-3476(05)80942-4 · 3.74 Impact Factor